|
SG10202112838YA
(en)
|
2008-04-09 |
2021-12-30 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
*
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
JP7178906B2
(ja)
|
2016-05-19 |
2022-11-28 |
ザ ジェネラル ホスピタル コーポレイション |
ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２
|
|
MX2019006072A
(es)
|
2016-11-30 |
2019-08-14 |
Oncomed Pharm Inc |
Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
IL272227B2
(en)
*
|
2017-07-27 |
2025-09-01 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
JP2021534196A
(ja)
|
2018-08-23 |
2021-12-09 |
シージェン インコーポレイテッド |
抗ｔｉｇｉｔ抗体
|
|
AU2019337974A1
(en)
|
2018-09-11 |
2021-04-08 |
iTeos Belgium SA |
Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
|
|
US11376255B2
(en)
|
2018-09-11 |
2022-07-05 |
iTeos Belgium SA |
Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
|
|
KR20210108978A
(ko)
|
2018-12-21 |
2021-09-03 |
오제 이뮈노테라프틱스 |
이작용성 항-pd-1/il-7 분자
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
US20200318200A1
(en)
|
2019-04-02 |
2020-10-08 |
The Brigham And Women's Hospital, Inc. |
Methods for Identifying Progression of a Primary Melanoma
|
|
KR102332847B1
(ko)
*
|
2019-06-13 |
2021-12-01 |
주식회사 녹십자 |
Tigit에 대한 항체 및 이의 용도
|
|
EP3986936A4
(en)
*
|
2019-06-21 |
2023-03-15 |
Single Cell Technology, Inc. |
ANTI-TIGIT ANTIBODIES
|
|
CN114728171A
(zh)
*
|
2019-11-05 |
2022-07-08 |
默克专利有限公司 |
抗tigit抗体及其应用
|
|
WO2021122866A1
(en)
|
2019-12-17 |
2021-06-24 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an il-7 variant
|
|
CN112409450B
(zh)
*
|
2020-03-29 |
2023-01-24 |
郑州大学 |
TIGIT-IgV的亲和剂及其应用
|
|
CN113563470B
(zh)
*
|
2020-04-29 |
2023-02-10 |
广州昂科免疫生物技术有限公司 |
结合tigit抗原的抗体及其制备方法与应用
|
|
CN115943312A
(zh)
|
2020-05-07 |
2023-04-07 |
法国居里学院 |
免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途
|
|
CN111995681B
(zh)
*
|
2020-05-09 |
2022-03-08 |
华博生物医药技术（上海）有限公司 |
抗tigit的抗体、其制备方法和应用
|
|
MX2022015157A
(es)
|
2020-06-02 |
2023-01-16 |
Arcus Biosciences Inc |
Anticuerpos para tigit.
|
|
KR20230024368A
(ko)
|
2020-06-18 |
2023-02-20 |
제넨테크, 인크. |
항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
|
|
WO2021258337A1
(en)
*
|
2020-06-24 |
2021-12-30 |
Huahui Health Ltd. |
Human monoclonal antibodies against tigit for immune related diseases
|
|
CN111718415B
(zh)
*
|
2020-07-03 |
2021-02-23 |
上海洛启生物医药技术有限公司 |
一种抗tigit纳米抗体及其应用
|
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
|
|
EP4192883A4
(en)
*
|
2020-08-05 |
2024-12-04 |
Crystal Bioscience Inc. |
Anti-tigit antibody and methods of use thereof
|
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
|
WO2022148781A1
(en)
|
2021-01-05 |
2022-07-14 |
Institut Curie |
Combination of mcoln activators and immune checkpoint inhibitors
|
|
EP4294948A1
(en)
|
2021-02-17 |
2023-12-27 |
iTeos Belgium SA |
Compounds, compositions and methods of treatment thereof
|
|
MX2023011964A
(es)
|
2021-04-09 |
2024-01-08 |
Ose Immunotherapeutics |
Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
|
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
WO2023010094A2
(en)
|
2021-07-28 |
2023-02-02 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
AU2023264591A1
(en)
|
2022-05-02 |
2024-11-07 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
|
KR20250022049A
(ko)
|
2022-06-07 |
2025-02-14 |
제넨테크, 인크. |
항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
|
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
|
JP2025525886A
(ja)
|
2022-08-02 |
2025-08-07 |
オーエスイー・イミュノセラピューティクス |
Ｃｄ２８に対する多機能性分子
|
|
EP4687991A1
(en)
|
2023-03-30 |
2026-02-11 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
WO2024200820A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025242836A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2025255297A1
(en)
*
|
2024-06-05 |
2025-12-11 |
Agilent Technologies, Inc. |
Anti-human tigit antibodies for in vitro diagnostics
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|
|
WO2026068705A1
(en)
|
2024-09-26 |
2026-04-02 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
|